MedPath

江苏安必生制药有限公司

Ownership
-
Established
2019-10-14
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

8

NMPA:8

Drug Approvals

Mesalazine Enteric-coated Tablets

Product Name
美沙拉嗪肠溶片
Approval Number
国药准字H20253977
Approval Date
Apr 22, 2025
NMPA

Cytarabine for Injection

Product Name
注射用阿糖胞苷
Approval Number
国药准字H20253065
Approval Date
Jan 2, 2025
NMPA

Cytarabine for Injection

Product Name
注射用阿糖胞苷
Approval Number
国药准字H20253066
Approval Date
Jan 2, 2025
NMPA

Agomelatine Tablets

Product Name
阿戈美拉汀片
Approval Number
国药准字H20249120
Approval Date
Oct 22, 2024
NMPA

Mesalazine Gastro-resistant Prolonged-release Granules

Product Name
美沙拉秦肠溶缓释颗粒
Approval Number
国药准字H20244970
Approval Date
Sep 26, 2024
NMPA

Mesalazine Enteric-coated Sustained-release Capsules

Product Name
美沙拉嗪肠溶缓释胶囊
Approval Number
国药准字H20244995
Approval Date
Sep 26, 2024
NMPA

Mesalazine Gastro-resistant Prolonged-release Granules

Product Name
美沙拉秦肠溶缓释颗粒
Approval Number
国药准字H20244969
Approval Date
Sep 26, 2024
NMPA

Acetylcysteine Effervescent Tablets

Product Name
乙酰半胱氨酸泡腾片
Approval Number
国药准字H20243168
Approval Date
Feb 6, 2024
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.